DOW JONES28,992.41-227.57 -0.78%
S&P 5003,337.75-35.48 -1.05%
NASDAQ9,576.59-174.38 -1.79%

SVB Leerink Maintains Outperform on Biogen, Raises Price Target to $410

SVB Leerink analyst Marc Goodman maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $350 to $410.

Benzinga · 02/06/2020 14:06

SVB Leerink analyst Marc Goodman maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $350 to $410.